{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T14:37:24Z","timestamp":1790260644328,"version":"4.1.0"},"reference-count":95,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP21cm0106406"],"award-info":[{"award-number":["JP21cm0106406"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007428","name":"Naito Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007428","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.intimp.2025.115010","type":"journal-article","created":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T14:55:00Z","timestamp":1749135300000},"page":"115010","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Mechanistic insights into the limited function of CAR-T cells in solid tumors and potential solutions"],"prefix":"10.1016","volume":"161","author":[{"given":"Taku","family":"Kouro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuro","family":"Sasada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kohzoh","family":"Imai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.intimp.2025.115010_bb0005","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1056\/NEJMoa1103849","article-title":"Chimeric antigen receptor\u2013modified t cells in chronic lymphoid leukemia","volume":"365","author":"Porter","year":"2011","journal-title":"N. Engl. J. Med."},{"issue":"16","key":"10.1016\/j.intimp.2025.115010_bb0010","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1215134","article-title":"Chimeric antigen receptor\u2013modified t cells for acute lymphoid leukemia","volume":"368","author":"Grupp","year":"2013","journal-title":"N. Engl. J. Med."},{"issue":"18","key":"10.1016\/j.intimp.2025.115010_bb0015","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","article-title":"Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma","volume":"380","author":"Raje","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.intimp.2025.115010_bb0020","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1038\/s41591-022-01800-8","article-title":"Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results","volume":"28","author":"Qi","year":"2022","journal-title":"Nat. Med."},{"issue":"14","key":"10.1016\/j.intimp.2025.115010_bb0025","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1056\/NEJMoa2210859","article-title":"GD2-CART01 for relapsed or refractory high-risk neuroblastoma","volume":"388","author":"Del Bufalo","year":"2023","journal-title":"N. Engl. J. Med."},{"issue":"399","key":"10.1016\/j.intimp.2025.115010_bb0030","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaa0984","article-title":"A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma","volume":"9","author":"O\u2019Rourke","year":"2017","journal-title":"Sci. Transl. Med."},{"issue":"10","key":"10.1016\/j.intimp.2025.115010_bb0035","doi-asserted-by":"crossref","DOI":"10.1002\/cti2.1154","article-title":"Severe delayed pulmonary toxicity following PD-L1-specific CAR-T cell therapy for non-small cell lung cancer","volume":"9","author":"Liu","year":"2020","journal-title":"Clin. Transl. Immunol."},{"issue":"4","key":"10.1016\/j.intimp.2025.115010_bb0040","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/mt.2010.24","article-title":"Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2","volume":"18","author":"Morgan","year":"2010","journal-title":"Mol. Ther."},{"issue":"11","key":"10.1016\/j.intimp.2025.115010_bb0045","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1007\/s00262-017-2034-7","article-title":"The clinical efficacy of first-generation carcinoembryonic antigen (CEACAM5)-specific CAR T cells is limited by poor persistence and transient pre-conditioning-dependent respiratory toxicity","volume":"66","author":"Thistlethwaite","year":"2017","journal-title":"Cancer Immunol. Immunother."},{"issue":"2","key":"10.1016\/j.intimp.2025.115010_bb0050","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1158\/2326-6066.CIR-13-0170","article-title":"Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies","volume":"2","author":"Beatty","year":"2014","journal-title":"Cancer Immunol. Res."},{"issue":"11","key":"10.1016\/j.intimp.2025.115010_bb0055","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1016\/j.ymthe.2019.07.015","article-title":"Phase I study of lentiviral-transduced chimeric antigen receptor-modified T cells recognizing mesothelin in advanced solid cancers","volume":"27","author":"Haas","year":"2019","journal-title":"Mol. Ther."},{"issue":"9","key":"10.1016\/j.intimp.2025.115010_bb0060","doi-asserted-by":"crossref","first-page":"3360","DOI":"10.1073\/pnas.0813101106","article-title":"Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains","volume":"106","author":"Carpenito","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"4","key":"10.1016\/j.intimp.2025.115010_bb0065","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/j.ccell.2025.03.019","article-title":"CAR-T therapy in solid tumors","volume":"43","author":"Du","year":"2025","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.intimp.2025.115010_bb0070","doi-asserted-by":"crossref","first-page":"1846926","DOI":"10.1080\/2162402X.2020.1846926","article-title":"Efficacy and biomarker analysis of CD133-directed CAR T cells in advanced hepatocellular carcinoma: a single-arm, open-label, phase II trial","volume":"9","author":"Dai","year":"2020","journal-title":"Oncoimmunology"},{"issue":"2","key":"10.1016\/j.intimp.2025.115010_bb0075","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001097","article-title":"HITM-SURE: hepatic immunotherapy for metastases phase Ib anti-CEA CAR-T study utilizing pressure enabled drug delivery","volume":"8","author":"Katz","year":"2020","journal-title":"J. Immunother. Cancer"},{"issue":"5","key":"10.1016\/j.intimp.2025.115010_bb0080","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1158\/2767-9764.CRC-22-0486","article-title":"Phase I trial of autologous RNA-electroporated cMET-directed CAR T cells administered intravenously in patients with melanoma and breast carcinoma","volume":"3","author":"Shah","year":"2023","journal-title":"Cancer Res. Commun."},{"issue":"12","key":"10.1016\/j.intimp.2025.115010_bb0085","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1158\/2326-6066.CIR-17-0189","article-title":"Safety and efficacy of Intratumoral injections of chimeric antigen receptor (CAR) T cells in metastatic breast Cancer","volume":"5","author":"Tchou","year":"2017","journal-title":"Cancer Immunol. Res."},{"issue":"3","key":"10.1016\/j.intimp.2025.115010_bb0090","first-page":"517","article-title":"Repeated peripheral infusions of anti-EGFRvIII CAR T cells in combination with pembrolizumab show no efficacy in glioblastoma: a phase 1 trial","volume":"5","author":"Bagley","year":"2024","journal-title":"Nat. Can."},{"key":"10.1016\/j.intimp.2025.115010_bb0095","article-title":"PD1 expression in EGFRvIII-directed CAR T cell infusion product for glioblastoma is associated with clinical response","volume":"13","author":"Tang","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2025.115010_bb0100","article-title":"First-in-human trial of EphA2-redirected CAR T-cells in patients with recurrent glioblastoma: a preliminary report of three cases at the starting dose","volume":"11","author":"Lin","year":"2021","journal-title":"Front. Oncol."},{"issue":"10","key":"10.1016\/j.intimp.2025.115010_bb0105","doi-asserted-by":"crossref","first-page":"2643","DOI":"10.1007\/s00432-021-03839-5","article-title":"GD2-specific chimeric antigen receptor-modified T cells for the treatment of refractory and\/or recurrent neuroblastoma in pediatric patients","volume":"148","author":"Yu","year":"2022","journal-title":"J. Cancer Res. Clin. Oncol."},{"issue":"571","key":"10.1016\/j.intimp.2025.115010_bb0110","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abd6169","article-title":"Antitumor activity without on-target off-tumor toxicity of GD2-chimeric antigen receptor T cells in patients with neuroblastoma","volume":"12","author":"Straathof","year":"2020","journal-title":"Sci. Transl. Med."},{"issue":"1","key":"10.1016\/j.intimp.2025.115010_bb0115","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.ccell.2023.11.011","article-title":"Immune determinants of CAR-T cell expansion in solid tumor patients receiving GD2 CAR-T cell therapy","volume":"42","author":"Kaczanowska","year":"2024","journal-title":"Cancer Cell"},{"issue":"9","key":"10.1016\/j.intimp.2025.115010_bb0120","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1016\/j.ymthe.2017.05.012","article-title":"CAR T cells administered in combination with lymphodepletion and PD-1 inhibition to patients with neuroblastoma","volume":"25","author":"Heczey","year":"2017","journal-title":"Mol. Ther."},{"key":"10.1016\/j.intimp.2025.115010_bb0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.102175","article-title":"RUNX-3-expressing CAR T cells targeting glypican-3 in patients with heavily pretreated advanced hepatocellular carcinoma: a phase I trial","volume":"63","author":"Fu","year":"2023","journal-title":"EClinicalMedicine"},{"issue":"9","key":"10.1016\/j.intimp.2025.115010_bb0130","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1002\/cac2.12472","article-title":"Combined local therapy and CAR-GPC3 T-cell therapy in advanced hepatocellular carcinoma: a proof-of-concept treatment strategy","volume":"43","author":"Shi","year":"2023","journal-title":"Cancer Commun (Lond)"},{"key":"10.1016\/j.intimp.2025.115010_bb0135","doi-asserted-by":"crossref","DOI":"10.1158\/2159-8290.CD-21-0407","article-title":"A phase I trial of regional mesothelin-targeted CAR T-cell therapy in patients with malignant pleural disease, in combination with the anti-PD-1 agent pembrolizumab","author":"Adusumilli","year":"2021","journal-title":"Cancer Discov."},{"issue":"2","key":"10.1016\/j.intimp.2025.115010_bb0140","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.ccell.2020.11.005","article-title":"Immunogenic chemotherapy enhances recruitment of CAR-T cells to lung Tumors and improves antitumor efficacy when combined with checkpoint blockade","volume":"39","author":"Srivastava","year":"2021","journal-title":"Cancer Cell"},{"issue":"4","key":"10.1016\/j.intimp.2025.115010_bb0145","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1097\/CJI.0000000000000260","article-title":"Pilot trial of adoptive transfer of chimeric antigen receptor-transduced T cells targeting EGFRvIII in patients with glioblastoma","volume":"42","author":"Goff","year":"2019","journal-title":"J. Immunother."},{"issue":"1","key":"10.1016\/j.intimp.2025.115010_bb0150","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1158\/2326-6066.CIR-17-0211","article-title":"High-affinity GD2-specific CAR T cells induce fatal encephalitis in a preclinical neuroblastoma model","volume":"6","author":"Richman","year":"2018","journal-title":"Cancer Immunol. Res."},{"issue":"2","key":"10.1016\/j.intimp.2025.115010_bb0155","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.jaip.2021.10.037","article-title":"Hypogammaglobulinemia after chimeric antigen receptor (CAR) T-cell therapy: characteristics, management, and future directions","volume":"10","author":"Wat","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"4","key":"10.1016\/j.intimp.2025.115010_bb0160","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/j.cell.2016.01.011","article-title":"Precision tumor recognition by T cells with combinatorial antigen-sensing circuits","volume":"164","author":"Roybal","year":"2016","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.intimp.2025.115010_bb0165","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1038\/s41467-020-20785-x","article-title":"Preclinical assessment of the efficacy and specificity of GD2-B7H3 SynNotch CAR-T in metastatic neuroblastoma","volume":"12","author":"Moghimi","year":"2021","journal-title":"Nat. Commun."},{"issue":"6534","key":"10.1016\/j.intimp.2025.115010_bb0170","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1126\/science.abc1855","article-title":"T cell circuits that sense antigen density with an ultrasensitive threshold","volume":"371","author":"Hernandez-Lopez","year":"2021","journal-title":"Science"},{"issue":"3","key":"10.1016\/j.intimp.2025.115010_bb0175","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1038\/mt.2013.262","article-title":"Kinetics of tumor destruction by chimeric antigen receptor-modified T cells","volume":"22","author":"Anurathapan","year":"2014","journal-title":"Mol. Ther."},{"issue":"8","key":"10.1016\/j.intimp.2025.115010_bb0180","doi-asserted-by":"crossref","first-page":"3036","DOI":"10.1172\/JCI83416","article-title":"Tandem CAR T cells targeting HER2 and IL13Ralpha2 mitigate tumor antigen escape","volume":"126","author":"Hegde","year":"2016","journal-title":"J. Clin. Invest."},{"issue":"May 2014","key":"10.1016\/j.intimp.2025.115010_bb0185","first-page":"1","article-title":"Technical reports a rapid and efficient single-cell manipulation method for screening antigen-specific antibody \u2013 secreting cells from human peripheral blood","volume":"4","author":"Jin","year":"2009","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.intimp.2025.115010_bb0190","doi-asserted-by":"crossref","DOI":"10.1038\/s42003-021-01791-1","article-title":"A single-chain antibody generation system yielding CAR-T cells with superior antitumor function","volume":"4","author":"Ochi","year":"2021","journal-title":"Commun. Biol."},{"issue":"1","key":"10.1016\/j.intimp.2025.115010_bb0195","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1038\/s41467-024-45378-w","article-title":"Mutation-specific CAR T cells as precision therapy for IGLV3-21(R110) expressing high-risk chronic lymphocytic leukemia","volume":"15","author":"M\u00e4rkl","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.intimp.2025.115010_bb0200","doi-asserted-by":"crossref","DOI":"10.1038\/nm.4431","article-title":"The activated conformation of integrin \u03b27 is a novel multiple myeloma-specific target for CAR T cell therapy","author":"Hosen","year":"2017","journal-title":"Nat. Med."},{"issue":"22","key":"10.1016\/j.intimp.2025.115010_bb0205","first-page":"7907","article-title":"Differential EphA2 epitope display on normal versus malignant cells","volume":"63","author":"Coffman","year":"2003","journal-title":"Cancer Res."},{"issue":"29","key":"10.1016\/j.intimp.2025.115010_bb0210","doi-asserted-by":"crossref","first-page":"30375","DOI":"10.1074\/jbc.M401218200","article-title":"Identification of the epitope for the epidermal growth factor receptor-specific monoclonal antibody 806 reveals that it preferentially recognizes an untethered form of the receptor","volume":"279","author":"Johns","year":"2004","journal-title":"J. Biol. Chem."},{"issue":"7","key":"10.1016\/j.intimp.2025.115010_bb0215","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1096\/fj.04-1766fje","article-title":"The antitumor monoclonal antibody 806 recognizes a high-mannose form of the EGF receptor that reaches the cell surface when cells over-express the receptor","volume":"19","author":"Johns","year":"2005","journal-title":"FASEB J."},{"key":"10.1016\/j.intimp.2025.115010_bb0220","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.664236","article-title":"High-affinity chimeric antigen receptor with cross-reactive scFv to clinically relevant EGFR oncogenic isoforms","volume":"11","author":"Thokala","year":"2021","journal-title":"Front. Oncol."},{"issue":"October 2016","key":"10.1016\/j.intimp.2025.115010_bb0225","article-title":"HEG1 is a novel mucin-like membrane protein that serves as a diagnostic and therapeutic target for malignant mesothelioma","volume":"7","author":"Tsuji","year":"2017","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.intimp.2025.115010_bb0230","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-018-32534-8","article-title":"Identification of mesothelioma-specific sialylated epitope recognized with monoclonal antibody SKM9-2 in a mucin-like membrane protein HEG1","volume":"8","author":"Matsuura","year":"2018","journal-title":"Sci. Rep."},{"issue":"10","key":"10.1016\/j.intimp.2025.115010_bb0235","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1002\/ijc.34843","article-title":"Novel chimeric antigen receptor-expressing T cells targeting the malignant mesothelioma-specific antigen sialylated HEG1","volume":"154","author":"Kouro","year":"2024","journal-title":"Int. J. Cancer"},{"issue":"1","key":"10.1016\/j.intimp.2025.115010_bb0240","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/s41417-021-00303-x","article-title":"Key chemokines direct migration of immune cells in solid tumors","volume":"29","author":"Kohli","year":"2022","journal-title":"Cancer Gene Ther."},{"issue":"3","key":"10.1016\/j.intimp.2025.115010_bb0245","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2017.1395997","article-title":"Intra-tumoral delivery of CXCL11 via a vaccinia virus, but not by modified T cells, enhances the efficacy of adoptive T cell therapy and vaccines","volume":"7","author":"Moon","year":"2018","journal-title":"Oncoimmunology"},{"issue":"11","key":"10.1016\/j.intimp.2025.115010_bb0250","doi-asserted-by":"crossref","first-page":"3193","DOI":"10.1016\/j.ymthe.2023.09.010","article-title":"CXCR4-modified CAR-T cells suppresses MDSCs recruitment via STAT3\/NF-\u03baB\/SDF-1\u03b1 axis to enhance efficacy against pancreatic cancer","volume":"31","author":"Sun","year":"2023","journal-title":"Mol. Ther."},{"issue":"14","key":"10.1016\/j.intimp.2025.115010_bb0255","doi-asserted-by":"crossref","first-page":"4719","DOI":"10.1158\/1078-0432.CCR-11-0351","article-title":"Expression of a functional CCR2 receptor enhances tumor localization and tumor eradication by retargeted human T cells expressing a mesothelin-specific chimeric antibody receptor","volume":"17","author":"Moon","year":"2011","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.intimp.2025.115010_bb0260","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1038\/s41467-022-29647-0","article-title":"Targeting brain lesions of non-small cell lung cancer by enhancing CCL2-mediated CAR-T cell migration","volume":"13","author":"Li","year":"2022","journal-title":"Nat. Commun."},{"issue":"15","key":"10.1016\/j.intimp.2025.115010_bb0265","doi-asserted-by":"crossref","first-page":"2432","DOI":"10.1158\/0008-5472.CAN-23-3007","article-title":"Human 3D ovarian Cancer models reveal malignant cell-intrinsic and -extrinsic factors that influence CAR T-cell activity","volume":"84","author":"Joy","year":"2024","journal-title":"Cancer Res."},{"issue":"12","key":"10.1016\/j.intimp.2025.115010_bb0270","doi-asserted-by":"crossref","first-page":"6166","DOI":"10.4049\/jimmunol.164.12.6166","article-title":"M-1\/M-2 macrophages and the Th1\/Th2 paradigm","volume":"164","author":"Mills","year":"2000","journal-title":"J. Immunol."},{"key":"10.1016\/j.intimp.2025.115010_bb0275","article-title":"Reprogramming tumour-associated macrophages to outcompete cancer cells","author":"Zhang","year":"2023","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.intimp.2025.115010_bb0280","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/s13045-019-0760-3","article-title":"Tumor-associated macrophages in tumor metastasis: biological roles and clinical therapeutic applications","volume":"12","author":"Lin","year":"2019","journal-title":"J. Hematol. Oncol."},{"issue":"6","key":"10.1016\/j.intimp.2025.115010_bb0285","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-004400","article-title":"PD-L1 blockade restores CAR T cell activity through IFN-gamma-regulation of CD163+ M2 macrophages","volume":"10","author":"Yamaguchi","year":"2022","journal-title":"J. Immunother. Cancer"},{"issue":"1","key":"10.1016\/j.intimp.2025.115010_bb0290","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1038\/s41467-021-20893-2","article-title":"CAR-T cell-mediated depletion of immunosuppressive tumor-associated macrophages promotes endogenous antitumor immunity and augments adoptive immunotherapy","volume":"12","author":"Rodriguez-Garcia","year":"2021","journal-title":"Nat. Commun."},{"issue":"5","key":"10.1016\/j.intimp.2025.115010_bb0295","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/j.immuni.2021.04.004","article-title":"MDSC: markers, development, states, and unaddressed complexity","volume":"54","author":"Hegde","year":"2021","journal-title":"Immunity"},{"issue":"8","key":"10.1016\/j.intimp.2025.115010_bb0300","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/nri1668","article-title":"Regulation of immune responses by L-arginine metabolism","volume":"5","author":"Bronte","year":"2005","journal-title":"Nat. Rev. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2025.115010_bb0305","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.ymthe.2020.09.034","article-title":"Olaparib suppresses MDSC recruitment via SDF1alpha\/CXCR4 Axis to improve the anti-tumor efficacy of CAR-T cells on breast Cancer in mice","volume":"29","author":"Sun","year":"2021","journal-title":"Mol. Ther."},{"issue":"9","key":"10.1016\/j.intimp.2025.115010_bb0310","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1158\/1078-0432.CCR-23-3841","article-title":"Mesothelin CAR T cells secreting anti-FAP\/anti-CD3 molecules efficiently target pancreatic adenocarcinoma and its stroma","volume":"30","author":"Wehrli","year":"2024","journal-title":"Clin. Cancer Res."},{"issue":"7","key":"10.1016\/j.intimp.2025.115010_bb0315","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.1111\/cas.14069","article-title":"Regulatory T (Treg) cells in cancer: can Treg cells be a new therapeutic target?","volume":"110","author":"Ohue","year":"2019","journal-title":"Cancer Sci."},{"issue":"1","key":"10.1016\/j.intimp.2025.115010_bb0320","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/cr.2016.151","article-title":"Regulatory T cells in cancer immunotherapy","volume":"27","author":"Tanaka","year":"2016","journal-title":"Cell Res."},{"issue":"2","key":"10.1016\/j.intimp.2025.115010_bb0325","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1073\/pnas.1812186116","article-title":"Differential control of human Treg and effector T cells in tumor immunity by fc-engineered anti\u2013CTLA-4 antibody","volume":"116","author":"Ha","year":"2018","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"7","key":"10.1016\/j.intimp.2025.115010_bb0330","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1084\/jem.20050940","article-title":"Treatment of advanced tumors with agonistic anti-GITR mAb and its effects on tumor-infiltrating Foxp3+CD25+CD4+regulatory T cells","volume":"202","author":"Ko","year":"2005","journal-title":"J. Exp. Med."},{"issue":"1","key":"10.1016\/j.intimp.2025.115010_bb0335","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1111\/imr.12939","article-title":"Regulatory B cells in cancer","volume":"299","author":"Michaud","year":"2021","journal-title":"Immunol. Rev."},{"issue":"10","key":"10.1016\/j.intimp.2025.115010_bb0340","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1158\/2326-6066.CIR-17-0075","article-title":"Antigen-presenting intratumoral B cells affect CD4+ TIL phenotypes in non\u2013small cell lung cancer patients","volume":"5","author":"Bruno","year":"2017","journal-title":"Cancer Immunol. Res."},{"issue":"1","key":"10.1016\/j.intimp.2025.115010_bb0345","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s12943-023-01737-7","article-title":"NK cells are never alone: crosstalk and communication in tumour microenvironments","volume":"22","author":"Zhou","year":"2023","journal-title":"Mol. Cancer"},{"issue":"18","key":"10.1016\/j.intimp.2025.115010_bb0350","doi-asserted-by":"crossref","first-page":"4778","DOI":"10.1182\/blood-2010-08-300954","article-title":"DNAM-1 ligand expression on ag-stimulated T lymphocytes is mediated by ROS-dependent activation of DNA-damage response: relevance for NK-T cell interaction","volume":"117","author":"Ardolino","year":"2011","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.intimp.2025.115010_bb0355","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.immuni.2016.05.001","article-title":"Lag-3, Tim-3, and TIGIT: co-inhibitory receptors with specialized functions in immune regulation","volume":"44","author":"Anderson Ana","year":"2016","journal-title":"Immunity"},{"issue":"8","key":"10.1016\/j.intimp.2025.115010_bb0360","doi-asserted-by":"crossref","first-page":"3130","DOI":"10.1172\/JCI83092","article-title":"Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition","volume":"126","author":"Cherkassky","year":"2016","journal-title":"J. Clin. Invest."},{"issue":"6316","key":"10.1016\/j.intimp.2025.115010_bb0365","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1126\/science.aaf2807","article-title":"Epigenetic stability of exhausted T cells limits durability of reinvigoration by PD-1 blockade","volume":"354","author":"Pauken","year":"2016","journal-title":"Science"},{"issue":"5","key":"10.1016\/j.intimp.2025.115010_bb0370","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a021873","article-title":"TGF-\u03b2 and the TGF-\u03b2 Family: Context-Dependent Roles in Cell and Tissue Physiology","volume":"vol. 8","author":"Morikawa","year":"2016","journal-title":"Cold Spring Harb. Perspect. Biol."},{"issue":"1","key":"10.1016\/j.intimp.2025.115010_bb0375","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1093\/abbs\/gmx127","article-title":"Paradoxical roles of TGF-\u03b2 signaling in suppressing and promoting squamous cell carcinoma","volume":"50","author":"Wu","year":"2018","journal-title":"Acta Biochim. Biophys. Sin. Shanghai"},{"issue":"4","key":"10.1016\/j.intimp.2025.115010_bb0380","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.133977","article-title":"TGF-\u03b2 inhibition via CRISPR promotes the long-term efficacy of CAR T cells against solid tumors","volume":"5","author":"Tang","year":"2020","journal-title":"JCI Insight"},{"key":"10.1016\/j.intimp.2025.115010_bb0385","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1146\/annurev-immunol-032713-120257","article-title":"TGF-\u03b2 activation and function in immunity","volume":"32","author":"Travis","year":"2014","journal-title":"Annu. Rev. Immunol."},{"issue":"12","key":"10.1016\/j.intimp.2025.115010_bb0390","first-page":"7239","article-title":"Signaling activity of transforming growth factor beta type II receptors lacking specific domains in the cytoplasmic region","volume":"13","author":"Wieser","year":"1993","journal-title":"Mol. Cell. Biol."},{"issue":"7","key":"10.1016\/j.intimp.2025.115010_bb0395","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1016\/j.ymthe.2018.05.003","article-title":"Dominant-negative TGF-\u03b2 receptor enhances PSMA-targeted human CAR T cell proliferation and augments prostate Cancer eradication","volume":"26","author":"Kloss","year":"2018","journal-title":"Mol. Ther."},{"issue":"6","key":"10.1016\/j.intimp.2025.115010_bb0400","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1038\/s41590-019-0346-9","article-title":"Adaptive plasticity of IL-10(+) and IL-35(+) T(reg) cells cooperatively promotes tumor T cell exhaustion","volume":"20","author":"Sawant","year":"2019","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.intimp.2025.115010_bb0405","doi-asserted-by":"crossref","DOI":"10.1038\/s41587-023-02060-8","article-title":"IL-10-expressing CAR T cells resist dysfunction and mediate durable clearance of solid tumors and metastases","author":"Zhao","year":"2024","journal-title":"Nat. Biotechnol."},{"issue":"Suppl. 2","key":"10.1016\/j.intimp.2025.115010_bb0410","doi-asserted-by":"crossref","first-page":"O11","DOI":"10.1186\/2051-1426-3-S2-O11","article-title":"Autologous HER2 CMV bispecific CAR T cells are safe and demonstrate clinical benefit for glioblastoma in a phase I trial","volume":"3","author":"Ahmed","year":"2015","journal-title":"J. Immunother. Cancer"},{"issue":"12","key":"10.1016\/j.intimp.2025.115010_bb0415","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1038\/nrc2540","article-title":"The impact of O2 availability on human cancer","volume":"8","author":"Bertout","year":"2008","journal-title":"Nat. Rev. Cancer"},{"issue":"2","key":"10.1016\/j.intimp.2025.115010_bb0420","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/leu.2015.247","article-title":"Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo","volume":"30","author":"Sommermeyer","year":"2016","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.intimp.2025.115010_bb0425","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1182\/blood-2012-05-431718","article-title":"IL-7 and IL-15 instruct the generation of human memory stem T cells from naive precursors","volume":"121","author":"Cieri","year":"2013","journal-title":"Blood"},{"issue":"14","key":"10.1016\/j.intimp.2025.115010_bb0430","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13143534","article-title":"IL-15 enhances the persistence and function of BCMA-targeting CAR-T cells compared to IL-2 or IL-15\/IL-7 by limiting CAR-T cell dysfunction and differentiation","volume":"13","author":"Battram","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.intimp.2025.115010_bb0435","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.immuni.2011.12.007","article-title":"Mitochondrial respiratory capacity is a critical regulator of CD8+ T cell memory development","volume":"36","author":"van der Windt","year":"2012","journal-title":"Immunity"},{"issue":"8010","key":"10.1016\/j.intimp.2025.115010_bb0440","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/s41586-024-07242-1","article-title":"FOXO1 enhances CAR T cell stemness, metabolic fitness and efficacy","volume":"629","author":"Chan","year":"2024","journal-title":"Nature"},{"issue":"8034","key":"10.1016\/j.intimp.2025.115010_bb0445","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1038\/s41586-024-07962-4","article-title":"The type 2 cytokine fc-IL-4 revitalizes exhausted CD8(+) T cells against cancer","volume":"634","author":"Feng","year":"2024","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.intimp.2025.115010_bb0450","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.immuni.2016.01.021","article-title":"Distinct Signaling of coreceptors regulates specific metabolism pathways and impacts memory development in CAR T cells","volume":"44","author":"Kawalekar","year":"2016","journal-title":"Immunity"},{"issue":"1","key":"10.1016\/j.intimp.2025.115010_bb0455","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.celrep.2017.09.015","article-title":"Tonic 4-1BB Costimulation in chimeric antigen receptors impedes T cell survival and is vector-dependent","volume":"21","author":"Gomes-Silva","year":"2017","journal-title":"Cell Rep."},{"issue":"5","key":"10.1016\/j.intimp.2025.115010_bb0460","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/s41422-023-00789-0","article-title":"Tuning charge density of chimeric antigen receptor optimizes tonic signaling and CAR-T cell fitness","volume":"33","author":"Chen","year":"2023","journal-title":"Cell Res."},{"issue":"10","key":"10.1016\/j.intimp.2025.115010_bb0465","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1038\/s41591-022-01969-y","article-title":"A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma","volume":"28","author":"Bachy","year":"2022","journal-title":"Nat. Med."},{"issue":"4","key":"10.1016\/j.intimp.2025.115010_bb0470","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1038\/nbt.4086","article-title":"IL-7 and CCL19 expression in CAR-T cells improves immune cell infiltration and CAR-T cell survival in the tumor","volume":"36","author":"Adachi","year":"2018","journal-title":"Nat. Biotechnol."},{"issue":"6","key":"10.1016\/j.intimp.2025.115010_bb0475","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/j.ccell.2021.04.014","article-title":"Conserved pan-cancer microenvironment subtypes predict response to immunotherapy","volume":"39","author":"Bagaev","year":"2021","journal-title":"Cancer Cell"}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576925010008?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576925010008?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T19:55:21Z","timestamp":1775764521000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576925010008"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":95,"alternative-id":["S1567576925010008"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2025.115010","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mechanistic insights into the limited function of CAR-T cells in solid tumors and potential solutions","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2025.115010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"115010"}}